28.3%
Phase 3 Weight Loss
12 mg dose at 80 weeks · TRIUMPH-1 (May 2026)
30.3%
Extended Treatment
BMI ≥35 continued to 104 weeks
5,800+
Phase 3 Participants
across 4 TRIUMPH trials · obesity, OSA, OA, CVD
18.2%
Discontinuation at 12 mg
vs 4% placebo · some flagged “excessive weight loss”
Head-to-Head: Weight Loss vs Alternatives
PubMed · RCT DataRetatrutide isn't a fringe peptide. It's an investigational triple-receptor agonist that — at the highest dose in Phase 3 — produces weight loss approaching what bariatric surgery delivers, without surgery. Here's how it stacks up against what's already on the market.
Mechanism: Three Receptors, Three Effects
PubMed · PharmacologySemaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits all three of the gut-hormone receptors at once — and the third (glucagon) is what unlocks the bigger weight-loss number. Here's what each receptor does inside the body.
GLP-1 Receptor
Appetite ↓
Suppresses appetite by acting on hypothalamic satiety circuits. Slows gastric emptying — food stays in the stomach longer, you feel full faster. Glucose-dependent insulin release from the pancreas (no hypoglycemia risk). This is what semaglutide (Wegovy / Ozempic) hits alone.
GIP Receptor
Insulin ↑
Potentiates insulin secretion when glucose is rising. Modulates fat storage and central appetite signals — the exact CNS role is still being mapped. Tirzepatide (Zepbound / Mounjaro) hits this PLUS GLP-1, and that's why it beats semaglutide.
Glucagon Receptor
Energy ↑
Increases energy expenditure — the body burns more calories at rest. Mobilizes liver fat — meaningful reductions in hepatic steatosis. This is the third lever retatrutide adds, and it's what stacks the extra ~6 percentage points of weight loss on top of tirzepatide.
Cardiac Side Effect
+6.7 bpm
Dose-dependent resting heart-rate increase. Peaks ~24 weeks, partially declines after. Larger than tirzepatide (~2-3 bpm) or semaglutide (~3-4 bpm). The glucagon agonism is the likely driver. Watch in cardiac patients.
Published & Ongoing Human Trials
PubMed · Clinical RCTsUnlike most peptide stories, retatrutide is backed by real Phase 2 and now Phase 3 randomized data — double-blind, placebo-controlled, registered on ClinicalTrials.gov, run at academic medical centers. Here are the trials, the sample sizes, and the outcomes.
| # | Study | Phase | n | Outcome (12 mg unless noted) |
|---|---|---|---|---|
| 1 |
Phase 2 NEJM — Adults with Obesity (Jastreboff et al.)
|
Phase 2 RCT | 338 | -24.2% body weight at 48 wk (vs -2.1% placebo) |
| 2 |
Phase 2 Body Composition Substudy (T2D, DXA-measured)
|
Phase 2 substudy | 189 | -26.1% total fat mass at 36 wk (8 mg pooled) |
| 3 |
TRIUMPH-1 — Phase 3 Obesity (Topline May 21, 2026)
|
Phase 3 RCT | ~2,000 | -28.3% body weight at 80 wk · -30.3% at 104 wk (BMI≥35 continued) |
| 4 |
TRIUMPH-2, -3, -4 — OSA, CVD, Knee OA basket trials
|
Phase 3 RCT | ~3,800 | Ongoing · readouts 2026-2028 |
| 5 |
TRANSCEND-CKD — Phase 2b Kidney Disease
|
Phase 2b RCT | 146 | Ongoing · primary endpoint at 24 wk (mGFR) |
Scale check: The full TRIUMPH program has enrolled 5,800+ participants across four registrational Phase 3 trials, plus the TRIUMPH-Outcomes cardio-kidney mortality trial (NCT06383390). This is one of the largest obesity-drug development programs in history.
Cost vs Weight-Loss Alternatives
Market Data · US 2026If you're treating clinically meaningful obesity (BMI ≥30, or ≥27 with weight-related comorbidities), what are the real options and what do they actually cost? Honest comparison of typical weight loss, monthly cost, and availability.
Free + Foundational
Diet + Exercise
$0
at minimum, no drug
3-5% weight loss typical
Required adjunct to any drug therapy
Required adjunct to any drug therapy
Semaglutide (Wegovy)
$150-1,349
/ month · compounded vs list
14.9% weight loss @ 68 wk
GLP-1 single agonist · FDA-approved
GLP-1 single agonist · FDA-approved
Tirzepatide (Zepbound)
$349-499
/ month · Lilly direct, cash
22.5% weight loss @ 72 wk
GLP-1 + GIP dual · FDA-approved
GLP-1 + GIP dual · FDA-approved
Not Yet Approved
Retatrutide (TBD brand)
Not retail
launch est. $1,000-1,400/mo
28.3% weight loss @ 80 wk
FDA approval expected 2027-2028
FDA approval expected 2027-2028
Permanent
Bariatric Surgery
$15K-25K
one-time, often covered
25-35% weight loss at 1-2 yr
Sleeve, bypass, SADI-S
Sleeve, bypass, SADI-S
Trial Dosing Protocol
PubMed · Phase 2/3 ProtocolsRetatrutide is a once-weekly subcutaneous injection with a ~6-day half-life. All trials use a dose-escalation schedule — starting low and stepping up monthly — specifically to reduce the GI side effects that knock 12-18% of patients out of treatment. No retail dose exists yet because FDA approval is pending; these are the trial protocols.
Maintenance Doses
4 mg / 9 mg / 12 mg
Once-weekly subcutaneous injection · three dose strengths tested in Phase 3 TRIUMPH-1, all three hit endpoints
Dose Escalation
2 → 4 → 8 → 12 mg
Monthly step-up. Lower starting dose (2 mg vs 4 mg) reduces nausea / vomiting / diarrhea peaks. Mandatory in trial design.
Treatment Duration
Chronic · ongoing
48 weeks (Phase 2) · 80 weeks (Phase 3 primary) · 104 weeks (continued) · Obesity is a chronic disease — the drug is taken indefinitely, not cycled. Weight regain follows discontinuation.
Critical Caveat
Investigational drug
Not FDA-approved. Cannot be legally prescribed in the U.S. except through enrolled clinical trial. Any retail "retatrutide" sold today is gray-market compounded peptide with unverified purity — not the Lilly molecule used in TRIUMPH.
Regulatory & Approval Status
T1 · Official AgenciesFDA (USA)
Not Approved — Phase 3
No NDA filed yet. Phase 3 TRIUMPH-1 topline announced positive May 21, 2026. Earliest plausible NDA filing window is Q4 2026 for the weight-management indication. Most likely FDA approval 2027 at earliest, possibly 2028.
Eli Lilly — Sponsor
Pivotal Trial Positive (TRIUMPH-1)
Topline May 21, 2026: all three doses (4 mg, 9 mg, 12 mg) met primary and key secondary endpoints over the 80-week primary period. 12 mg cohort averaged 28.3% weight loss; BMI≥35 patients continued to 104 weeks reached 30.3%. Lilly trades as LLY on NYSE; full TRIUMPH program continues through 2026-2028.
WADA / Sports
Will be banned on approval
Every GLP-1-class drug is treated as a Prohibited Substance for competitive athletes via the WADA "Metabolic Modulators" / "Non-Approved Substances" categories. Retatrutide will follow on FDA approval. Not a current concern for non-competitive users.
Compounding Status
Gray-Market — Buyer Beware
"Retatrutide" sold today by research-peptide vendors is NOT the Lilly molecule from TRIUMPH. It's a compounded approximation with unverified purity and unverified dose. Lilly holds the patent; only Lilly has access to the actual investigational compound until FDA approval.
The Investigators Behind the Data
Academic · First/Senior Authors
These are the academic physicians who designed and ran the trials — not podcast hosts, not influencers. Their findings are the source for every number on this page.
Dr. Ania M. Jastreboff, MD, PhD
PI · Phase 2 + 3
First author on the Phase 2 NEJM trial that established retatrutide's 24.2% weight loss at 48 weeks (n=338). Principal investigator on Phase 3 TRIUMPH-1 — the registrational trial whose May 2026 readout produced the 28.3% / 30.3% headline numbers. Director, Yale Obesity Research Center. Professor of Medicine (Endocrinology) and Pediatrics at Yale School of Medicine. Her stated position: “Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease.”
Dr. Lee M. Kaplan, MD, PhD
TRIUMPH Design
Co-investigator on the Phase 2 NEJM trial alongside Jastreboff. Co-author on the TRIUMPH program design paper (Diabetes Obes Metab, 2025), which laid out the basket-trial methodology that simultaneously evaluates retatrutide for obesity, obstructive sleep apnea, and knee osteoarthritis. Director, Obesity and Metabolism Institute. Faculty appointment, Harvard Medical School / Massachusetts General Hospital. One of the most-cited obesity-medicine researchers of the past two decades.
Eli Lilly Research Team
LY3437943
The Lilly molecular team (Coskun, Bunck, Haupt, Milicevic, Hartman, Harris) designed retatrutide as a synthetic triple agonist with a half-life of ~6 days, enabling once-weekly subcutaneous dosing. They are senior authors on the Phase 2 body-composition substudy (Lancet Diabetes Endocrinol, 2025) showing -26.1% total fat mass at the 8 mg dose. Same team is running TRANSCEND-CKD (kidney) and TRIUMPH-Outcomes (cardio-kidney) trials. Lilly holds the patent — nothing labeled "retatrutide" outside their trial program is the actual molecule.
Dr. Christos S. Mantzoros, MD, DSc
Pipeline Review
Senior author on the 2024 Pharmacological Reviews systematic review identifying 53 emerging obesity drug trials, placing retatrutide at the top tier of the incretin-based pipeline. Professor of Medicine, Harvard Medical School. Editor-in-chief of Metabolism. His finding: Phase 2 incretin-class trials showed 7.4-24.2% mean weight loss across the field — retatrutide sits at the top end of that range and the Phase 3 readout has now confirmed it.
Community Voices & User Reports
Anecdotal · Real-World Voices
This section is anecdotal — intentionally. The trial data above is the science. This section is what real people inside the trials and outside them are actually saying. Positive AND negative voices are included to balance the Lilly-published Phase 3 headlines. Not controlled, not blinded — included for honest context.
Dr. Ashley Froese, MD
Independent MD
The non-Lilly, non-academic voice on this drug class. Board-certified family-medicine physician running a Direct Primary Care clinic (Mesa, AZ) and the This Is Not Covered peptide-education channel. She covers the GLP-1 / peptide weight-loss class — mechanism, dosing logic, safety, and the gray-market compounding reality — independent of any drugmaker. Her consistent themes: these are chronic treatments, not quick fixes, and the gap between clean trial data and unverified compounded sourcing is the real-world risk. (Covers the class broadly; no retatrutide-specific published statement located as of this page's date.)
Trial Participants — Positive
76.7% Goal-Met
Published qualitative exit-interview study of 36 Phase 2 trial participants on retatrutide. 76.7% reported achieving their weight-reduction goal. Participants described eating less often (n=31), feeling more in control of eating, improvements in mobility (n=27), energy levels (n=24), social activities (n=18), exercise (n=19), and clothing size (n=24). Most reported feeling more self-confident (n=32) and happy (n=25).
Trial Participants — Frustrations
3 of 36
From the SAME peer-reviewed exit-interview study — three participants reported frustration due to disappointing weight loss (their weight loss didn't meet expectations). Two reported reduced social participation from adverse events; another two from new eating habits. Not everyone wins on this drug. Individual response varies meaningfully, including in trial conditions with monitored care.
Compounded Retatrutide Users
$50-70/mo
The reality outside the trial: most people accessing “retatrutide” in 2026 are buying lyophilized peptide powder from research-peptide vendors at $50-70/month, with no prescription and no Lilly quality controls. Purity is unverified — the molecule may be genuine but the manufacturing chain isn't. Real anecdotal weight-loss reports exist; so do reports of injection-site reactions, dosing errors, and counterfeit product.
STAT News — Critical Reporting
18.2% Quit
Independent biomedical journalism flagged the 18.2% discontinuation rate at the 12 mg dose as a complicating factor beneath the headline-grabbing efficacy numbers. Eli Lilly attributed some of those discontinuations to “perceived excessive weight loss” — meaning patients reached their goal and stopped — but the framing is contested. STAT also raised sustainability questions: obesity is chronic, the drug is taken indefinitely, weight regain follows discontinuation, and at projected pricing the lifetime cost is substantial.
New to Retatrutide? Start Here.
If semaglutide (Wegovy) opened the GLP-1 era and tirzepatide (Zepbound) raised the ceiling, retatrutide just kicked the ceiling out. It's Eli Lilly's investigational triple-receptor drug — one injection a week, three gut-hormone receptors hit simultaneously, and 28.3% body-weight loss at the top dose in Phase 3. It's not on the market yet. Here's everything you need to know in plain English.
What it is
A once-weekly injectable drug developed by Eli Lilly (also called LY3437943). It's a triple-receptor agonist — meaning one molecule activates three different gut-hormone receptors at the same time: GLP-1, GIP, and glucagon. Currently in Phase 3 trials. Not FDA-approved.
What it does
Three things at once: suppresses your appetite (GLP-1), boosts insulin response (GIP), and increases the calories your body burns at rest (glucagon). The glucagon piece is the key extra lever — it's what stacks on top of what Wegovy / Zepbound already do. Result in Phase 3: 28.3% average body-weight loss at 80 weeks.
How it's given
One subcutaneous injection per week (same pattern as Ozempic or Mounjaro). Dose escalation over several months: typically 2 mg → 4 mg → 8 mg → 12 mg, stepping up monthly to manage nausea. Treatment is chronic — ongoing, not a finite cycle. Stopping the drug typically leads to weight regain.
Can I get it?
Not legally, not yet. Retatrutide is not FDA-approved; the only way to access the real Lilly molecule today is through enrolled clinical trials. NDA filing expected Q4 2026, FDA approval most likely 2027-2028. The "retatrutide" sold by gray-market peptide vendors is NOT the Lilly molecule — it's compounded with unverified purity.
Worth waiting for?
If your weight-loss goals are big and the GLP-1 options aren't quite enough, yes — if you're patient. The 28.3% Phase 3 number is real, achieved in a 5,800-participant program with a credible safety profile (the discontinuation rate is high but partly because people lost more weight than they wanted). In the meantime, tirzepatide is approved, available, and delivers ~22.5%.
Common Questions, Honest Answers
The questions people actually ask when they first hear about retatrutide. Answers grounded in the published Phase 2 + Phase 3 trial data, not speculation.
How does this compare to Ozempic / Wegovy?
Same drug class (gut-hormone agonist), different math. Semaglutide (Ozempic / Wegovy) hits one receptor (GLP-1) and produces ~14.9% weight loss at 68 weeks. Retatrutide hits three and produces 28.3% at 80 weeks — roughly double the weight loss in similar trial conditions. Both are once-weekly subcutaneous injections; retatrutide is just a more aggressive molecule.
And vs. Zepbound / Mounjaro (tirzepatide)?
Tirzepatide hits two receptors (GLP-1 + GIP) and produces ~22.5% weight loss. Retatrutide adds the third receptor (glucagon), which is what stacks the extra ~6 percentage points on top. Tirzepatide is approved and available now; retatrutide is not.
When can I actually get a prescription?
Eli Lilly is expected to file the New Drug Application with the FDA in Q4 2026 or early 2027. Standard FDA review takes 10-12 months for a priority drug. Earliest realistic retail availability: late 2027. More likely 2028. Insurance coverage will be its own fight after that.
What are the side effects?
Same class signature as other GLP-1 drugs — dose-related and mostly GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort. Specific to retatrutide: a resting heart-rate increase of ~6.7 bpm at the highest dose (peaks ~24 weeks, then partially declines), larger than tirzepatide (~2-3 bpm) or semaglutide (~3-4 bpm). The glucagon agonism is the likely driver.
How many people quit because of side effects?
In Phase 3: 12.2% at the 9 mg dose and 18.2% at the 12 mg dose discontinued, vs 4% on placebo. Eli Lilly noted that some discontinuations were for "perceived excessive weight loss" — meaning patients reached their goal and stopped. That muddies the safety read but is genuine evidence of efficacy.
How much weight will I lose, realistically?
Trial data: at 12 mg over 80 weeks, the average participant lost 28.3% of starting body weight. Continuing to 104 weeks (and limited to patients with BMI ≥35) bumps that to 30.3%. Individual results vary widely — some participants lost less, some lost considerably more.
Will the weight stay off if I stop?
Probably not. Obesity is a chronic disease, and like blood pressure medication, stopping the drug typically leads to gradual return. Trials of semaglutide and tirzepatide both show meaningful weight regain after discontinuation. Retatrutide is expected to follow the same pattern — current thinking is that it's a chronic, ongoing treatment, not a finite course.
Does it work for type 2 diabetes too?
Yes — and it was first tested there. The Phase 2 program included diabetic participants and showed strong HbA1c reductions plus body-fat-mass loss of -26.1% at the 8 mg dose. The Phase 3 TRIUMPH program is primarily obesity-focused but includes a CVD-population trial (TRIUMPH-3) and the TRANSCEND-CKD kidney-disease trial.
What about sleep apnea, knee arthritis, fatty liver?
Lilly is testing all of these. TRIUMPH-1 and -2 nest obstructive sleep apnea and knee osteoarthritis sub-protocols inside their weight-management trials. TRIUMPH-4 is a standalone knee-OA trial. Animal data and Phase 2 substudies also show meaningful liver fat reduction. Multiple secondary indications could land alongside obesity approval.
What will it cost?
Lilly hasn't announced launch pricing. Reasonable estimate based on tirzepatide list price ($1,349/mo for Wegovy, $349-499/mo for Zepbound via Lilly Direct): retatrutide will likely launch at $1,000-1,400/month list, with copay assistance for commercial insurance and a Lilly-Direct cash option similar to Zepbound's. Coverage will vary — Medicare currently does not cover anti-obesity drugs.
Is the "retatrutide" sold online today the real drug?
No. Eli Lilly holds the patent and exclusively manufactures the investigational compound for its trials. Anything labeled "retatrutide" sold by research-peptide vendors right now is compounded by third parties with unverified purity and unverified potency. Buying gray-market is buying a guess. If you want the real drug, wait for FDA approval or enroll in a trial.
Smartest play if I want to lose weight today?
Three options consistently emerge from the data: (1) start tirzepatide (Zepbound) now — FDA-approved, $349-499 direct, ~22.5% weight loss; or (2) enroll in a TRIUMPH trial if you meet eligibility (drug is free, real Lilly molecule, monitored care); or (3) start tirzepatide now and plan to switch to retatrutide when FDA-approved in 2027-2028 if your weight goals exceed what tirzepatide delivers. Talk to a real obesity-medicine physician, not a med-spa.
Key Takeaways
- 28.3% weight loss at 12 mg over 80 weeks in Phase 3 TRIUMPH-1 — the largest weight-loss result from any incretin-class drug in trials to date
- Mechanism is the real story: three receptors, three effects (appetite, insulin, energy expenditure) — semaglutide hits one, tirzepatide hits two, retatrutide hits all three
- One injection per week, subcutaneous, with monthly dose escalation to manage GI side effects
- Not FDA-approved yet — expected NDA filing Q4 2026, approval most likely 2027-2028
- Anything sold today labeled "retatrutide" outside the Lilly trial program is compounded and not the real molecule
- For now, tirzepatide (Zepbound) is the strongest approved option; retatrutide is what's next